CAT-1004 regulatory update

FDA granted Fast Track designation to Catabasis’ CAT-1004 to treat Duchenne muscular dystrophy (DMD). The conjugate of salicylate and docosahexaenoic acid (DHA) that inhibits activated NF-kappa B ( NF...